GP6 and androgen insensitivity syndrome: The Acute Ischemic Stroke Interventional phase 1b/2a Trial (ACTIMS) targeted platelet GPVI by applying glenzocimab, a Fab fragment against human GPVI (Fig. 1B), within three hours after AIS onset in addition to alteplase with or without EVT [43].